山東新華製藥股份(00719.HK)2個品種中標藥品集中採購
格隆匯1月20日丨山東新華製藥股份(00719.HK)公告,2020年1月17日,公司參加了聯合採購辦公室(“聯採辦”)組織的第二批全國藥品集中採購的投標工作。公司根據《國家食品藥品監督管理總局關於發佈化學藥品註冊分類改革工作方案的公告》,按化學藥品新註冊分類批准的仿製藥品格列美脲片(1mg、2mg)、頭孢拉定膠囊(0.25g)參加了本次集中採購,2個品種三個規格均中標本次集中採購,並且公司根據各省區市場潛力進行了省區遴選。就上述中標品種,格列美脲片在本次5家中標企業中,中標價格位列第二高位,頭孢拉定膠囊在本次3家中標企業中,中標價格最高。
本次中標將有利於本公司充分發揮格列美脲原料藥及製劑一體化生產優勢,且公司已經做好充分的生產準備,可以確保本標期內(三年)的原料藥和製劑市場供應。
本次中標將有利於上述產品在通過一致性評價後,快速擴大其國內市場的銷售覆蓋面,提高市場佔有率和品牌影響力,有利於推進公司“大製劑戰略”實施步伐,對公司未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.